Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Dingli, David  [Clear All Filters]
2019
Sidana, S., M Sidiqi, H., Dispenzieri, A., Buadi, F.K., Lacy, M.Q., Muchtar, E., Dingli, D., Hayman, S.R., Gonsalves, W.I., Kapoor, P., et al. (2019). 15 Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis.Am J Hematol.
Hwa, Y.L., Gertz, M.A., Kumar, S.K., Lacy, M.Q., Buadi, F.K., Dingli, D., Kapoor, P., Zeldenrust, S.R., Leung, N., Hayman, S.R., et al. (2019). Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.Leukemia.
2018
M Sidiqi, H., Aljama, M.A., Muchtar, E., Buadi, F.K., Warsame, R., Lacy, M.Q., Dispenzieri, A., Dingli, D., Leung, N., Gonsalves, W.I., et al. (2018). Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75.Biol Blood Marrow Transplant.
Père, N.Mon, Lenaerts, T., Pacheco, J.M., and Dingli, D. (2018). Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria.Plos Comput Biol14, e1006133.
M Sidiqi, H., Aljama, M., Jevremovic, D., Muchtar, E., Buadi, F.K., Warsame, R., Lacy, M.Q., Dispenzieri, A., Dingli, D., Gonsalves, W.I., et al. (2018). Prognostic significance of stringent complete response post stem cell transplantation in AL amyloidosis.Biol Blood Marrow Transplant.
2016
Muchtar, E., Dispenzieri, A., Kumar, S.K., Dingli, D., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Kapoor, P., Leung, N., Chakraborty, R., et al. (2016). Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.Haematologica.
Hwa, Y.L., Kumar, S.K., Gertz, M.A., Lacy, M.Q., Buadi, F.K., Kourelis, T.V., Gonsalves, W.I., S Rajkumar, V., Go, R.S., Leung, N., et al. (2016). Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation.Am J Hematol.
Kourelis, T.V., Nasr, S.H., Dispenzieri, A., Kumar, S.K., Gertz, M.A., Fervenza, F.C., Buadi, F.K., Lacy, M.Q., Erickson, S.B., Cosio, F.G., et al. (2016). Outcomes of patients with renal monoclonal immunoglobulin deposition disease.Am J Hematol.
2015
Cordes, S., Gertz, M.A., Buadi, F.K., Lin, Y., Lacy, M.Q., Kapoor, P., Kumar, S.K., McCurdy, A., Dispenzieri, A., Dingli, D., et al. (2015). Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.Blood Coagul Fibrinolysis.
Mir, M.A., Kapoor, P., Kumar, S., Pandey, S., Dispenzieri, A., Lacy, M.Q., Dingli, D., Hogan, W., Buadi, F., Hayman, S., et al. (2015). Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic.Clin Lymphoma Myeloma Leuk.
2014
Gertz, M.A., and Dingli, D. (2014). How we manage autologous stem cell transplantation for patients with multiple myeloma.Blood.
2013
Kourelis, T.V., Kumar, S.K., Srivastava, G., Gertz, M.A., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Zeldenrust, S.R., Leung, N., Kyle, R.A., et al. (2013). Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.Am J Hematol.